Navigation Links
Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals, Inc. (Amex: PRW), a company "Advancing Drugs Through Glycoscience(R)", today updated the progress of its Phase II clinical trial for first-line treatment of metastatic, unresectable colorectal cancer patients who are unable to tolerate irinotecan and/or oxaliplatin, and its Phase II clinical trial for first-line treatment of biliary cancer patients. Treatment for both indications may represent orphan drug status for DAVANAT(R), the Company's target delivery compound. In addition, the Company plans to submit the manufacturing data requested by the FDA this year for DAVANAT(R) 505 (b)(2) filings as a functional excipient.

Phase II, First Line Treatment, Colorectal Cancer Trial

To date, eight patients have been dosed with DAVANAT(R) in combination with 5-FU, Avastin(R) and leucovorin. Two patients have tumor shrinkage of greater than 30%, a partial response according to Response Evaluation Criteria for Solid Tumors (RECIST). Five patients have stable disease for up to seven months and one had non-drug related progressive disease. Patients experienced no increase in drug-related toxicity and reduced side effects with increased exposure to 5-FU and AVASTIN(R). The Simon two-stage designed study is an open-label, multi-center trial. The primary objectives of the trial are tumor shrinkage and progression-free survival. Six sites are actively recruiting patients. Additional sites are expected to be active shortly. Nine of 25 (36%) end-stage colorectal cancer patients from Phase I/II trials were stabilized from 2 to 8 months.

Phase II, First Line Treatment, Biliary Cancer Trial

To date, seven patients have been dosed with DAVANAT(R) in combination with 5-FU. One patient has tumor shrinkage of greater than 30%, a partial response according to RECIST. Five patients have stable disease for up to five months and one had non-drug related
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. NCCN Updates Esophageal and Gastric Cancer Guidelines
5. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
6. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
10. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
11. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
Post Your Comments:
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources ... brought about by the Affordable Care Act ... prescribing of pharmaceutical therapies. The ACA altered ... through new regulations and expanded access via ... the health exchanges—state-based marketplaces set up by ...
(Date:7/31/2014)... LISBON, Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval ... The inspection, carried out by the FDA Consumer Safety ... initially planned, started on 21 st July and concluded ... to be compliant with the principles and guidelines of Good ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
(Date:8/1/2014)... Did you know that July was ... is to raise awareness across the country and to educate ... According to the American Cancer Society, nearly 5,000 Americans are ... new soft tissue sarcomas will be diagnosed. , “A ... they are other kinds of cancer,” said Dr. Chawla, a ...
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, “It ... newly released article entitled, “ 5 Signs That Your ... ,” Clean Crawls explains the need to replace insulation ... critters. , Get a free attic insulation or ... http://www.cleancrawl.com/contact . , If crawl space or attic insulation ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
(Date:8/1/2014)... 2014 The Multiple System Atrophy Coalition, a ... caregivers and families affected by the neurological disorder Multiple System ... La Coste, TX to its Board of Directors. , Sharon ... Eric Sutton. He was diagnosed officially with MSA in 2010 ... his family. Like many others with this rare disorder it ...
(Date:8/1/2014)... WA (PRWEB) August 01, 2014 Blindness is ... be argued that the scientists of today, despite well-meaning efforts, ... to providing a definite treatment for reversing blindness that does ... that sense, this is where alternative medicine takes the “slack” ... rely on expensive treatments or harmful surgeries. , Alternative ...
Breaking Medicine News(10 mins):Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2
... Cloning Livestock From,Differentiated Donor Cells, AUSTIN, Texas, ... that the U.S. Patent and Trademark Office has,granted ... of,cloning ungulate animals, fetuses and embryos using differentiated ... of patents and patent,applications owned by Roslin Institute ...
... N.C., Dec. 11 Quintiles,Transnational Corp. today announced ... and General Counsel., Previously Senior Vice President, ... in 1998 as Vice President, European,Legal Affairs., ... the clinical,research industry, having served the company in ...
... Brings More Than 30 Years Experience to ... Personal Therapeutic Device Leader, ... INCR) manufacturer of the RESPeRATE(R) hypertension treatment,device, clinically-proven to significantly ... Vice President of Sales. Dube,brings more than 30 years of ...
... WILLIAMSVILLE, N.Y., Dec. 11 The office of,Congressman ... Leadership,Award for voting against huge cuts in Medicare ... Reynolds received the award from The,Coalition for Medicare ... strengthen Medicare Choices., David Trumpfheller, Coalition Member ...
... Amedica Corporation, an,orthopedic implants company focused on silicon ... and Drug Administration,has granted a Special 510(k) marketing ... The Valeo VBR spinal implant is intended for ... stabilization of the thoracolumbar spine.,The Valeo VBR incorporates ...
... Valued at Over $96,000, LIVINGSTON, N.J., Dec. ... announced today that its wholly-owned,subsidiary, Genotec Nutritionals, Inc., ... sales from the distribution of its branded,products and ... closed on a large order for a new ...
Cached Medicine News:Health News:Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents 2Health News:InterCure Names Scot Dube Vice President of Sales 2Health News:InterCure Names Scot Dube Vice President of Sales 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:MM2 Group Closes Sale for New Fish Oil Product 2Health News:MM2 Group Closes Sale for New Fish Oil Product 3
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
... EDS 3 CSF External Drainage System was developed ... physicians. The clinicians who work every day with ... EDS 3: ease-of-use in an integrated pole clamp, ... accurate hydrostatic leveling from a unique laser leveling ...
... Trippi-Wells and Universal tongs were developed for ... than can be safely provided for with ... construction. Kit complete with four skull pins ... pin application. Skull pins at 10 angle. ...
Cruchfield Skull Traction Tong, small pattern....
Medicine Products: